Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8185829 | 0.98 | CA2 (0.61) | CA2CYP2C9CYP2C19RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL3818358 | 0.98 | CA2 (0.61) | CA2CYP2C9CYP2C19RAB9ANPC1 | |
| SCHEMBL12809543 | 0.94 | CA2 (0.57) | CA2CYP2C9CYP2C19RAB9ANPC1 | |
| SCHEMBL9157209 | 0.88 | LTA4H (0.52) | CA2L3MBTL1 | |
| SCHEMBL11290860 | 0.87 | CA2 (0.80) | CA2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5659578 | 0.87 | CA2 (0.50) | CA2CYP2C9CYP2C19RAB9ANPC1 | |
| SCHEMBL10923300 | 0.85 | CA2 (0.48) | CA2CYP2C9CYP2C19RAB9ANPC1 | |
| SCHEMBL1512090 | 0.82 | CYP2C9 (0.52) | CA2CYP2C9CYP2C19RAB9ANPC1 | |
| SCHEMBL17501386 | 0.81 | CA2 (0.64) | CA2LMNA | |
| SCHEMBL9449852 | 0.81 | CA2 (0.64) | CA2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 671 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119595796-A | Sampling detection method for phenacetin content | 华中药业股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118443832-A | Method for detecting parachlorophenylacetamide in paracetamol vitamin C effervescent tablet | 江苏和汇医药科技有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-118258923-A | Method for detecting impurity content in aminomethyl guaifenesin compound preparation by HPLC method | 四川逢春制药有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-114965754-B | Method for detecting related substances and bacteriostat in acetaminophen tablet | 陕西必康制药集团控股有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-115097049-A | Method for determining related substances in pediatric paracetamol, atificial cow-bezoar and chlorphenamine maleate granules | 广西壮族自治区食品药品检验所 | 2022-09-23 | — | — | CN | claimed |
| CN-115078576-A | Analysis method of related substances of paracetamol dihydrocodeine tablets | 陕西九州制药有限责任公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114965754-A | Method for detecting related substances and bacteriostatic agent in acetaminophen tablet | 陕西必康制药集团控股有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114062554-A | Analysis method for simultaneously determining acetaminophen ibuprofen-related substances | 山东百诺医药股份有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-112526017-A | Method for detecting contents of various impurities in amimetu-yusu compound preparation by using HPLC (high performance liquid chromatography) method | 四川逢春制药有限公司 | 2021-03-19 | — | — | CN | claimed |
| EP-3697791-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS Innopharm (Shanghai) Ltd. (CN) | 2020-08-26 | — | — | EP | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| JP-2002501024-A | — | — | 2002-01-15 | — | — | JP | claimed |
| US-20020002168-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2002-01-03 | — | — | US | claimed |
| US-20010041705-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2001-11-15 | — | — | US | claimed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | claimed |
| US-6277852-B1 | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC | 2001-08-21 | — | — | US | claimed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| EP-0957099-A2 | Heterocyclic carboxamides | Pfizer Products Inc. (US) | 1999-11-17 | — | — | EP | claimed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | claimed |
| WO-1994024095-A1 | IMMUNOSUPPRESSIVE AGENTS | ABBOTT LABORATORIES (US) | 1994-10-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002168-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | CA2 1080/4885CYP2C9 795/4885CYP2C19 518/4885 |
| US-20010041705-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | CA2 1080/4885CYP2C9 795/4885CYP2C19 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.